Is there new hope for people with progressive forms of multiple sclerosis?

This week at the American Academy of Neurology Conference, MedDay, a Paris based biotechnology company, will present research where patients with progressive multiple sclerosis showed improvements in standard measures of disability after taking large doses of biotin in a phase III study. Open access to the full pilot study is available at http://www.msard-journal.com/article/S2211-0348(15)00006-1/abstract
Learn more about the development of MD1003 at the MedDay website http://www.medday-pharma.com/research-development/pipeline/md1003/
"The research platform identififes new therapeutic targets through cerebrospinal fluid metabolic analysis" http://www.medday-pharma.com/research-development/research-platform/


High doses of biotin in chronic progressive multiple sclerosis: A pilot study - Multiple...
www.msard-journal.com
Evolution of visual evoked potentials in patient 4 (whole field, 24×32, mean curves). On the left side, although no individualized P100 wave could be observed on the left before treatment (M0), a P100 wave was well confirmed after 9 months (M9) with a normal latency of 104 ms. On the right side, a P…